trials, although short and low-risk, are still governed by regulatory frameworks. Before starting human studies, sponsors must obtain authorization from national health authorities. This ensures that human subjects are protected and the study is scientifically and ethically justified.

This tutorial walks you through the step-by-step process for submitting regulatory applications for Phase 0 studies in the U.S. (FDA), Europe (EMA), and India (CDSCO).

Step 1: Understand the Regulatory Pathway

The first step is identifying the regulatory framework applicable to Phase 0 (exploratory) trials:

• FDA (USA): Exploratory IND under the 2006 guidance
• EMA (EU): Scientific Advice + CTA under EU Clinical Trials Regulation
• CDSCO (India): Clinical Trial Application under Schedule Y (Pilot/Exploratory Studies)

Each authority requires specific preclinical data, documentation format, and submission procedures.

Step 2: Preclinical Requirements

Unlike full Phase 1 submissions, Phase 0 requires a limited but robust nonclinical data package:

• Single-dose toxicity data in one rodent species
• Genotoxicity screening (e.g., Ames test)
• Pharmacokinetic (ADME) data from animal models
• Safety pharmacology (optional if justified)

All studies must follow GLP (Good Laboratory Practice) standards.

Step 3: Prepare the Investigational Medicinal Product (IMP) Dossier

Include detailed chemistry, manufacturing, and control (CMC) data for the microdose formulation:

• Active Pharmaceutical Ingredient (API) specifications
• Formulation composition, dose strength, and stability
• Batch records and certificates of analysis
• Sterility/pyrogen data (for injectables)

Ensure that the manufacturing facility is GMP-certified or qualified for clinical material preparation.

Step 4: Draft the Clinical Trial Protocol

Your protocol should clearly outline:

• Study objectives and endpoints (e.g., PK, PD, imaging)
• Number of participants (typically 6–15)
• Dose (≤100 μg or 1/100th therapeutic dose)
• Route and schedule of administration
• Inclusion/exclusion criteria and safety monitoring

Include stopping rules and risk minimization strategies.

Step 5: Prepare the Investigator’s Brochure (IB)

This document summarizes all known information about the investigational product:

• Pharmacology, toxicology, and ADME profile
• CMC and formulation details
• Prior in vitro and animal study results

The IB must be current, referenced, and scientifically justified.

Step 6: Submit the Application Package

For FDA (USA)

• File an Exploratory IND to the Division of Microbiology or relevant therapeutic area
• Follow 21 CFR Part 312 structure: Module 1–5 (eCTD)
• Include cover letter, preclinical summary, protocol, and IB

For EMA (EU)

• Apply for Scientific Advice if exploratory use of microdose
• Submit Clinical Trial Application (CTA) to the EU Portal
• Follow ICH CTD format and country-specific language/translations

For CDSCO (India)

• Prepare the Form CT-04 and Form CT-06 for trial permission
• Submit through SUGAM portal or hard copy with CD format
• Include preclinical dossier, protocol, IB, ethics approvals, and insurance details

Step 7: Ethics Committee (EC/IRB) Approval

Simultaneously, submit the protocol and informed consent documents to:

• IRB (Institutional Review Board) in the U.S.
• REC (Research Ethics Committee) in the EU
• IEC (Institutional Ethics Committee) in India (registered with CDSCO)

Include participant protection plan, ICF template, and risk communication strategy.

Step 8: Register the Trial

Before first enrollment, ensure registration on recognized platforms:

• ClinicalTrials.gov (U.S.)
• EudraCT or EU-CTR (EU)
• CTRI – Clinical Trials Registry India

Include brief summary, endpoints, sponsor details, and regulatory approval reference numbers.

Step 9: Site Readiness and Investigator Training

Ensure the trial site is GCP-compliant and ready with:

• Trained investigators and backup medical staff
• Emergency equipment and SOPs in place
• Drug accountability and documentation systems

Investigators must be trained on the investigational product, protocol, and consent process.

Step 10: Await Regulatory Authorization and Begin Trial

Typical timelines for approval:

• FDA: 30 days (if no clinical hold is issued)
• EMA: Up to 60 days (varies by country and central review)
• CDSCO: 60–90 days depending on dossier completeness

Begin trial only after receiving both regulatory and ethics approvals.

Summary for Clinical Research Students

Phase 0 regulatory submissions may be lighter than full-scale trials, but they still demand rigor, structure, and accountability. As a student or professional in regulatory affairs, clinical operations, or early-phase development, learning how to prepare a strong submission equips you for a strategic role in bringing therapies to the clinic—faster and more ethically.

By following these 10 steps, you’ll ensure your Phase 0 trial is compliant, efficient, and ready for first-in-human research.